19 years of historical data (2007–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Puma Biotechnology, Inc. trades at 9.3x earnings, 84% below its 5-year average of 58.2x, sitting at the 33rd percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 61%. On a free-cash-flow basis, the stock trades at 6.9x P/FCF, 12% below the 5-year average of 7.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $287M | $301M | $150M | $206M | $190M | $124M | $406M | $339M | $772M | $3.7B | $1.0B |
| Enterprise Value | $286M | $300M | $155M | $233M | $228M | $177M | $442M | $399M | $816M | $3.6B | $828M |
| P/E Ratio → | 9.34 | 9.75 | 4.92 | 9.62 | 208.37 | — | — | — | — | — | — |
| P/S Ratio | 1.26 | 1.32 | 0.65 | 0.87 | 0.83 | 0.49 | 1.80 | 1.25 | 3.08 | 132.64 | — |
| P/B Ratio | 2.22 | 2.31 | 1.63 | 3.85 | 8.80 | — | — | 19.43 | 22.51 | 68.93 | 4.87 |
| P/FCF | 6.89 | 7.22 | 3.85 | 14.33 | — | 5.98 | — | 15.37 | — | — | — |
| P/OCF | 6.87 | 7.21 | 3.85 | 7.62 | — | 5.98 | 507.56 | 15.16 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Puma Biotechnology, Inc.'s enterprise value stands at 7.7x EBITDA, roughly in line with its 5-year average of 7.6x. The Healthcare sector median is 13.8x, placing the stock at a 45% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.31 | 0.67 | 0.99 | 1.00 | 0.70 | 1.96 | 1.47 | 3.25 | 131.44 | — |
| EV / EBITDA | 7.67 | 8.05 | 3.64 | 5.27 | 6.80 | 14.06 | — | — | — | — | — |
| EV / EBIT | 7.67 | — | 4.23 | 6.47 | 18.93 | — | — | — | — | — | — |
| EV / FCF | — | 7.20 | 3.98 | 16.20 | — | 8.57 | — | 18.10 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Puma Biotechnology, Inc. earns an operating margin of 16.3%. Operating margins have expanded from 13.9% to 16.3% over the past 3 years, signaling improving operational efficiency. ROE of 28.0% indicates solid capital efficiency. ROIC of 24.7% represents excellent returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.5% | 74.5% | 72.1% | 73.4% | 75.8% | 74.8% | 82.5% | 86.5% | 86.2% | 79.8% | — |
| Operating Margin | 16.3% | 16.3% | 13.4% | 13.9% | 10.4% | 0.5% | -13.5% | -27.8% | -37.7% | -1055.6% | — |
| Net Profit Margin | 13.6% | 13.6% | 13.1% | 9.2% | 0.0% | -11.5% | -26.7% | -27.8% | -45.3% | -1054.2% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 28.0% | 28.0% | 41.6% | 57.5% | 0.0% | — | -1042.3% | -292.0% | -259.3% | -222.0% | -132.8% |
| ROA | 14.5% | 14.5% | 13.6% | 9.5% | 0.0% | -12.4% | -25.0% | -30.6% | -53.5% | -139.6% | -112.1% |
| ROIC | 24.7% | 24.7% | 26.2% | 35.0% | 32.1% | 2.4% | -42.5% | -72.9% | -145.1% | -1239.8% | -218.7% |
| ROCE | 29.6% | 29.6% | 24.9% | 23.7% | 18.1% | 1.0% | -22.2% | -45.0% | -63.3% | -181.3% | -130.9% |
Solvency and debt-coverage ratios — lower is generally safer
Puma Biotechnology, Inc. carries a Debt/EBITDA ratio of 0.8x, which is very conservative (75% below the sector average of 3.1x). The company holds a net cash position — cash of $30M exceeds total debt of $29M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | 0.80 | 2.09 | 5.29 | — | — | 6.88 | 4.43 | 0.91 | — |
| Debt / EBITDA | 0.77 | 0.77 | 1.74 | 2.52 | 3.41 | 9.26 | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | 0.05 | 0.50 | 1.76 | — | — | 3.45 | 1.27 | -0.62 | -0.93 |
| Net Debt / EBITDA | -0.03 | -0.03 | 0.11 | 0.61 | 1.13 | 4.25 | — | — | — | — | — |
| Debt / FCF | — | -0.03 | 0.13 | 1.87 | — | 2.59 | — | 2.73 | — | — | — |
| Interest Coverage | — | — | 2.49 | 2.45 | 2.05 | 0.10 | -2.16 | -5.04 | -8.61 | -406.11 | -288.73 |
Net cash position: cash ($30M) exceeds total debt ($29M)
Short-term solvency ratios and asset-utilisation metrics
Puma Biotechnology, Inc.'s current ratio of 2.00x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.57x to 2.00x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.00 | 2.00 | 1.54 | 1.57 | 1.73 | 1.28 | 1.28 | 1.83 | 3.02 | 1.82 | 6.31 |
| Quick Ratio | 1.93 | 1.93 | 1.45 | 1.50 | 1.67 | 1.21 | 1.25 | 1.80 | 2.99 | 1.79 | 6.31 |
| Cash Ratio | 1.20 | 1.20 | 1.05 | 0.97 | 1.05 | 0.75 | 0.82 | 1.23 | 1.62 | 1.40 | 5.19 |
| Asset Turnover | — | 1.06 | 1.08 | 1.02 | 1.03 | 1.12 | 0.92 | 1.16 | 0.97 | 0.17 | — |
| Inventory Turnover | 10.55 | 10.55 | 7.38 | 8.85 | 12.17 | 8.96 | 11.40 | 11.61 | 13.18 | 2.76 | — |
| Days Sales Outstanding | — | 85.75 | 50.70 | 75.11 | 67.66 | 46.90 | 41.42 | 38.74 | 31.92 | 127.42 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Puma Biotechnology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 10.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 10.7% | 10.3% | 20.3% | 10.4% | 0.5% | — | — | — | — | — | — |
| FCF Yield | 14.5% | 13.8% | 26.0% | 7.0% | — | 16.7% | — | 6.5% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $51M | $49M | $48M | $45M | $41M | $40M | $39M | $38M | $37M | $33M |
Compare PBYI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| PBYIYou | $287M | 9.3 | 7.7 | 6.9 | 74.5% | 16.3% | 28.0% | 24.7% | 0.8 |
| RVMD | $20B | -17.1 | — | — | — | — | -58.1% | -54.3% | — |
| INCY | $20B | 15.8 | 11.9 | 14.8 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| GMAB | $18B | 15.4 | 14.9 | 15.1 | 95.4% | 31.1% | 23.0% | 22.2% | 0.1 |
| EXEL | $12B | 15.8 | 13.2 | 13.4 | — | 37.6% | 35.5% | 32.1% | 0.2 |
| IBRX | $10B | -15.8 | — | — | 100.0% | -2334.2% | — | — | — |
| MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
| CELC | $5B | -39.5 | — | — | — | — | -87.5% | -50.3% | — |
| CGON | $5B | -41.7 | — | — | 100.0% | -10067.3% | -19.2% | -26.3% | — |
| ERAS | $4B | -19.8 | — | — | — | — | -43.7% | -39.2% | — |
| IDYA | $3B | -25.2 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 19 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PBYI stacks up against sector leader Revolution Medicines, Inc..
Start ComparisonPuma Biotechnology, Inc.'s current P/E ratio is 9.3x. The historical average is 8.1x. This places it at the 33th percentile of its historical range.
Puma Biotechnology, Inc.'s current EV/EBITDA is 7.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 7.6x.
Puma Biotechnology, Inc.'s return on equity (ROE) is 28.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -88.6%.
Based on historical data, Puma Biotechnology, Inc. is trading at a P/E of 9.3x. This is at the 33th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Puma Biotechnology, Inc. has 74.5% gross margin and 16.3% operating margin. Operating margin between 10-20% is typical for established companies.
Puma Biotechnology, Inc.'s Debt/EBITDA ratio is 0.8x, indicating low leverage. A ratio below 2x is generally considered financially healthy.